Market sentiment shifted toward defensive plays as traders moved capital away from assets sensitive to energy sector fluctuations. Healthcare firms benefited from this rotation, providing a buffer for portfolios against broader market instability. The legal landscape for the industry remains complex, however, following the recent appellate decision. The court's move to revive the litigation creates a fresh wave of scrutiny for manufacturers of acetaminophen-based products. Plaintiffs in these cases contend that prenatal exposure to the drug carries significant developmental risks, a claim that will now proceed through the judicial system despite previous attempts to dismiss the consolidated actions.